EGFR and cancer: There is also evidence that constitutive STAT3 activation plays a prominent role in mediating drug resistance to many targeted cancer therapies and chemotherapies, including the poor response to the EGFR blockade, with less than 15% of patients benefiting from cetuximab as a single agent or 36% when combined with chemotherapy [111].